New hope for pancreatic cancer: targeted drug combo enters Mid-Stage trial

NCT ID NCT06770439

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase II study tests a new drug called IBI343, which targets a protein on cancer cells, combined with standard chemotherapy (gemcitabine and albumin-bound paclitaxel) in 64 people with advanced pancreatic cancer. The trial has two parts: a safety lead-in and a randomized extension. Researchers will measure how many patients' tumors shrink and track side effects. The goal is to see if this combination works better than chemotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI343 (a drug that targets a protein on cancer cells, linked to a chemotherapy agent) plus gemcitabine and albumin-bound paclitaxel
What this could lead to: If it works, this could offer a new treatment option for people with advanced pancreatic cancer that has a specific protein (CLDN18.2).
What could go wrong: This is an early phase II trial with only 64 participants, so results are not definitive. The drug combination may cause side effects like blood or liver toxicity, and it may not improve outcomes compared to standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC CANCERS

Contacts and locations

Locations

First Affiliated Hospital of Zhejiang University Schlool of Medicine
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310000, China
the First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.